Therapies on the market or in development for rosacea treat either the symptomatic flushing or the inflammatory skin lesions. Signum Dermalogix Inc.'s lead small molecule isoprenylcysteine analog could treat both aspects of rosacea by targeting key inflammatory pathways.

The isoprenylcysteine (IPC) motif occurs in multiple G proteins that interact with the intracellular domains of G protein-coupled receptors (GPCRs). These interactions regulate multiple processes, including the secretion of pro-inflammatory cytokines.